These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 27816693)

  • 1. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
    Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
    Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
    Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
    Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
    Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
    J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.
    Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
    Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V
    J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
    Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M
    Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
    Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
    Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up.
    Pokorná Z; Kollárová-Brázdová P; Lenčová-Popelová O; Jirkovský E; Kubeš J; Mazurová Y; Adamcová M; Holečková M; Palička V; Šimůnek T; Štěrba M
    Clin Sci (Lond); 2022 Jan; 136(1):139-161. PubMed ID: 34878093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
    Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
    J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Pokorna Z; Jirkovsky E; Hlavackova M; Jansova H; Jirkovska A; Lencova-Popelova O; Brazdova P; Kubes J; Sotakova-Kasparova D; Mazurova Y; Adamcova M; Vostatkova L; Holzerova K; Kolar F; Simunek T; Sterba M
    Clin Sci (Lond); 2019 Aug; 133(16):1827-1844. PubMed ID: 31409729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
    Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
    Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
    Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A
    Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.
    Simůnek T; Sterba M; Popelová O; Kaiserová H; Adamcová M; Hroch M; Hasková P; Ponka P; Gersl V
    Br J Pharmacol; 2008 Sep; 155(1):138-48. PubMed ID: 18536744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
    Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V
    Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.
    Li W; Xu B; Xu J; Wu XL
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
    Dziegiel P; Jethon Z; Suder E; Sopel M; Rabczyński J; Surowiak P; Zabel M
    Exp Toxicol Pathol; 2002 Feb; 53(6):433-9. PubMed ID: 11926284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy.
    Fulbright JM; Egas-Bejar DE; Huh WW; Chandra J
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1297-307. PubMed ID: 26515054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
    Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
    Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
    Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
    Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.